The pharmaceutical community is abuzz with anticipation surrounding retatrutide, a new dual GIP and GLP-1 agonist that’s exhibiting significant promise in clinical trials for addressing obesity. Unlike some available weight loss approaches, retatrutide appears to offer a more substantial loss in body weight and improve metabolic markers, particul